Argos Therapeutics Inc.: Argos Therapeutics Announces Filing of Its Annual Report on Form 10-K

Tickers: ARGS
DURHAM, N.C., April 7, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS) announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2013 with the Securities and Exchange Commission.

A copy of the Annual Report on Form 10-K is available to be viewed or downloaded from the Investors section of Argos's website at Argos stockholders or other interested parties may obtain a hard copy of the Annual Report on Form 10-K, free of charge, by contacting Argos's Investor Relations Department at: 4233 Technology Drive, Durham, NC 27704, or by email at:

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
About Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos' most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal cell carcinoma (mRCC). The company also plans to report data from its Phase 2b trial of AGS-004 for the treatment of HIV in


         Andrea Coan

         Berry & Company Public Relations

         (212) 253-8881



         Angeli Kolhatkar

         Burns McClellan

         (212) 213-0006
distributed by

This noodl was issued by Argos Therapeutics Inc. and was initially posted at It was distributed, unedited and unaltered, by noodls on 2014-04-07 23:41:21 CET. The issuer is solely responsible for the accuracy of the information contained therein.